415 related articles for article (PubMed ID: 9333042)
21. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
22. Glycopeptide tolerance in bacteria causing endocarditis.
Perry JD; Jones AL; Gould FK
J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
[TBL] [Abstract][Full Text] [Related]
23. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.
Arthur M; Depardieu F; Reynolds P; Courvalin P
Antimicrob Agents Chemother; 1999 Aug; 43(8):1875-80. PubMed ID: 10428906
[TBL] [Abstract][Full Text] [Related]
24. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
26. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
27. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Cormican MG; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
[TBL] [Abstract][Full Text] [Related]
28. MIC distribution and inoculum effect of LY333328: a study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care unit patient surveillance cultures.
Cantón R; Mir N; Sánchez M; Baquero F
Clin Microbiol Infect; 1999 Sep; 5(9):554-559. PubMed ID: 11851708
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
Zeckel ML; Preston DA; Allen BS
Antimicrob Agents Chemother; 2000 May; 44(5):1370-4. PubMed ID: 10770782
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
Rolston KV; Nguyen H; Messer M
Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
[TBL] [Abstract][Full Text] [Related]
31. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
32. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
Brown DF; Courvalin P
Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of staphylococci and enterococci to glycopeptides comparison of 3 test methods.
Jansen B; Schumacher-Perdreau F; Pulverer G
Zentralbl Bakteriol; 1995 Oct; 282(4):402-8. PubMed ID: 9810663
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
36. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
37. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
39. Teicoplanin Chemistry and Microbiology.
Parenti F; Schito GC; Courvalin P
J Chemother; 2000 Nov; 12 Suppl 5():5-14. PubMed ID: 11131964
[TBL] [Abstract][Full Text] [Related]
40. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
